Unesbulin
Phase 1Small molecule
Unesbulin is one of 62 small molecule programs targeting Leiomyosarcoma. It is currently in Phase 1.
2
Indications
3
Total Trials
0
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Phase 3
Perjeta
RochePhase 3
Aromasin
PfizerPhase 3
IV Iron
PfizerPhase 3
Rina-S
GenmabPhase 3
Defactinib
VVerastem, Inc.
Phase 3
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
GSK5733584
GSKPhase 3
Doxorubicin HCL Liposome
AAccelerated Community Oncology Research Network
Phase 3
Standard Single Agent Chemotherapy
FFondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Unesbulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPTC Therapeutics